Suppr超能文献

他汀类药物暴露与周围神经病变风险之间的关联:一项荟萃分析。

The association between statins exposure and peripheral neuropathy risk: A meta-analysis.

作者信息

Wang Miao, Li Muqin, Xie Ying

机构信息

Department of Endocrinology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

出版信息

J Clin Pharm Ther. 2021 Aug;46(4):1046-1054. doi: 10.1111/jcpt.13393. Epub 2021 Feb 25.

Abstract

WHAT IS KNOWN AND OBJECTIVE

Statins are widely used lipid-lowering drugs and play an important role in the treatment of many cardiovascular diseases. With the increase in the scope of use and the number of users, peripheral neuropathy caused by statins has been frequently reported. There are no randomized controlled trials comparing the relationship between statins and the risk of peripheral neuropathy. Therefore, we systematically reviewed and meta-analysed observational studies evaluating the impact of statins on the risk of peripheral neuropathy.

METHODS

PubMed, Embase, the Cochrane Library databases and Web of Science were used to search the effects of statins on polyneuropathy from inception to 3 December 2020. We included studies that met the following criteria: (i) A randomized controlled trial, prospective or retrospective cohort study examining the relationship between statins and peripheral neuropathy (PN). Exclusion criteria included the following: Reviews and research related to other diseases or subjects; and studies without data on the prevalence of PN were excluded. Newcastle-Ottawa scale (NOS) was used for quality assessment of included studies. Meta-analysis was used to estimate the risk of disease. We conducted a subgroup analysis of duration of follow-up, adjusted (adjusted RR vs. unadjusted RR), sample size, study design and region.

RESULTS AND DISCUSSION

A total of 9 independent studies assessing 150 556 patients were included in this analysis. In this meta-analysis, we found that there was a nonsignificant increase of PN with statins exposure (RR 1.26, 95% CI (0.92-1.74)). Our results revealed that there was no significant association between statins exposure and peripheral neuropathy risk.

WHAT IS NEW AND CONCLUSION

Statins exposure does not influence the risk of developing peripheral neuropathy. The quality of the evidence included in this study is low, but it can provide useful information for clinicians.

摘要

已知信息与研究目的

他汀类药物是广泛使用的降脂药物,在多种心血管疾病的治疗中发挥着重要作用。随着使用范围和使用人数的增加,他汀类药物引起的周围神经病变屡有报道。目前尚无比较他汀类药物与周围神经病变风险之间关系的随机对照试验。因此,我们对评估他汀类药物对周围神经病变风险影响的观察性研究进行了系统综述和荟萃分析。

方法

使用PubMed、Embase、Cochrane图书馆数据库和Web of Science检索从起始至2020年12月3日他汀类药物对多发性神经病变的影响。我们纳入了符合以下标准的研究:(i)一项随机对照试验、前瞻性或回顾性队列研究,考察他汀类药物与周围神经病变(PN)之间的关系。排除标准包括:与其他疾病或主题相关的综述和研究;以及无PN患病率数据的研究。采用纽卡斯尔-渥太华量表(NOS)对纳入研究进行质量评估。使用荟萃分析估计疾病风险。我们对随访时间、调整情况(调整后的RR与未调整的RR)、样本量、研究设计和地区进行了亚组分析。

结果与讨论

本分析共纳入9项评估150556例患者的独立研究。在这项荟萃分析中,我们发现他汀类药物暴露使PN有非显著性增加(RR 1.26,95%CI(0.92 - 1.74))。我们的结果显示,他汀类药物暴露与周围神经病变风险之间无显著关联。

新发现与结论

他汀类药物暴露不影响发生周围神经病变的风险。本研究纳入证据的质量较低,但可为临床医生提供有用信息。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验